Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mesenchymal Stem Cells for Polycystic Ovary Syndrome
NCT06143527Phase 1Recruiting
- Sponsor
- The Foundation for Orthopaedics and Regenerative Medicine
- Start
- Nov 2023
- Primary completion
- Nov 2027
- Modality
- Stem Cell Therapies
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of mesenchymal stem cells in polycystic ovary syndrome (PCOS), sponsored by The Foundation for Orthopaedics and Regenerative Medicine. Primary endpoint: Adverse Events at 4 years. Started Nov 2023; status: recruiting.
02
Drugs
mesenchymal stem cells
03
Conditions
polycystic ovary syndrome (PCOS)
Beyond the preview
Go deeper on NCT06143527.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06143527.